Meanwhile, the EFFORT trial (NCT03579316) investigated the Wee1 inhibitor adavosertib alone and in combination with olaparib in patients with PARPi-resistant ovarian cancer, demonstrating notable efficacy in this challenging patient population [107]. Here, WEE1 is linked to ovarian cancer.